Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneron Pharmaceuticals is conducting a real-world evidence study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study aims to estimate the incidence of retinal vasculitis (RV) events in patients receiving aflibercept intravitreal (IVT) therapy, commonly known as Eylea® 2mg, in US clinical practice. This research is significant as it seeks to confirm RV cases identified through ICD-10-CM codes and identify RV with occlusion.
The intervention being tested is the drug aflibercept 2 mg, administered intravitreally. It is intended to treat patients aged 18 and older who have initiated this therapy during the study period.
This observational study follows a cohort model with a retrospective time perspective. It does not involve any specific allocation, intervention model, or masking, as its primary purpose is descriptive.
The study began on December 24, 2024, with the latest update submitted on August 19, 2025. These dates mark the study’s initiation and the most recent information update, indicating ongoing recruitment and data collection.
The study’s findings could influence Regeneron’s stock performance and investor sentiment, as successful results may enhance the market position of Eylea® in treating retinal conditions. Investors should also consider the competitive landscape, as advancements in similar treatments by other companies could impact market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.